Pharmafile Logo

value

- PMLiVE

UK market access: The importance of a local value story

Meeting the needs of the health service’s new stakeholders

- PMLiVE

Outcomes shape the new European payer networks

In the new commercial reality of cost-constrained healthcare environments the payer is everywhere

- PMLiVE

Malaria vaccine gives “unprecedented” results

Able to protect 12 out of 15 people in phase I trial

Roche's Perjeta pertuzumab

Roche’s breast cancer drug too expensive for NHS use

But pharma company says UK Government dithering on Perjeta patient access scheme

- PMLiVE

Building and delivering market access capabilities in emerging markets

Local skills gaps must be addressed if the potential of the BRIC countries is to be realised

- PMLiVE

Modern values in healthcare

Understanding the new concepts and processes of value will be the first steps towards adapting to a new healthcare environment

- PMLiVE

The CementBloc strengthens its payer strategy expertise

The CementBloc boosts its US payer strategy team and capabilities to help US clients navigate shifting payer landscape

- PMLiVE

Pfizer wins new European approval for Prevenar 13

Expands use of pneumococcal disease vaccine to cover people aged 18 to 49

- PMLiVE

Novartis enters developing nations vaccines partnership

Will work with Biological E to deliver vaccines for typhoid and paratyphoid A fevers

- PMLiVE

Interview: David Haslam, NICE

The new chair of the UK’s NICE discusses navigating the stormy waters of health service reforms, collaborating with pharma and the introduction of VBP

Really? Another innovative product?

Is innovation really at the heart of what we offer, or has it simply become an ancient tradition?

- PMLiVE

Rebooting the innovation engine

How can the industry transform the efficacy of its R&D teams so they can do more with less?

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links